Jackson Square Capital LLC Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Jackson Square Capital LLC bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 9,651 shares of the biotechnology company's stock, valued at approximately $1,441,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP bought a new stake in shares of Ascendis Pharma A/S in the first quarter valued at approximately $992,000. Price T Rowe Associates Inc. MD grew its position in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Ascendis Pharma A/S by 4,231.4% during the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company's stock worth $11,419,000 after purchasing an additional 73,796 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock valued at $1,664,000 after buying an additional 4,338 shares during the last quarter. Finally, Evolutionary Tree Capital Management LLC lifted its stake in shares of Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock valued at $3,391,000 after buying an additional 11,223 shares during the period.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $2.81 on Thursday, hitting $126.55. The company's stock had a trading volume of 266,595 shares, compared to its average volume of 401,763. The company has a 50 day moving average price of $132.54 and a 200 day moving average price of $133.30. Ascendis Pharma A/S has a fifty-two week low of $86.54 and a fifty-two week high of $161.00. The company has a market capitalization of $7.67 billion, a PE ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -7.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ASND. Wells Fargo & Company upped their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. Oppenheimer reissued an "outperform" rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. TD Cowen increased their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, Citigroup lifted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $195.92.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.